All In Biotech

Drug Trial Radar · NCT00689936

Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma

A Phase III, Randomized, Open-label, 3-arm Study to Determine the Efficacy and Safety of Lenalidomide(REVLIMID) Plus Low-dose Dexamethasone When Given Until Progressive Disease or for 18 Four-week Cycles Versus the Combination of Melphalan, Prednisone, and Thalidomide Given for 12 Six-week Cycles in Patients With Previously Untreated Multiple Myeloma Who Are Either 65 Years of Age or Older or Not Candidates for Stem Cell Transplantation.

Last checked: Nov 19, 2026Latest source record: Nov 20, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,623 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,623

Actual

Start

Aug 21, 2008

Primary completion

Jul 14, 2016

Study completion Jul 14, 2016

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jun 4, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the safety and efficacy of Lenalidomide plus low dose dexamethasone to that of the combination of melphalan, prednisone and thalidomide.

Conditions

  • Multiple Myeloma

Interventions

  • Lenalidomide and low-dose dexamethasoneDrug

    Lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg 20mg, or 25 mg capsules, given either days 1-21 of each 28 day cycles or given every other day for 21 days until documentation of PD. Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle up to disease progression

  • Lenalidomide plus low-dose dexamethasone given for 18 four-week cyclesDrug

    lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg, 20 mg or 25 mg capsules given on days 1-21 of each 28 day cycle or every other day for 21 days for 18 cycles. Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle for 18 cycles

  • Melphalan, Prednisone and ThalidomideDrug

    Melphalan - oral, 2mg tablets dosed at either 0.25mg/kg, 0.125 mg/kg, 0.20mg/kg or 0.10mg/kg on days 1-4 of each 42 day cycle up to 12 cycles Prednisone - oral, 5mg, 10mg, 20 mg and 50 mg tablets dosed at 2mg/kg daily days 1-4 of each 42 day cycle for up to 12 cycles Thalidomide - oral, 50mg, 100mg and 200 mg capsules dosed at either 100mg or 200 mg daily on days 1-41 of each 42 day cycle for up to 12 cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Kaplan-Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Independent Review Adjudication Committee (IRAC)Time frame: From date of randomization until the data cut-off date of 24 May 2013. Median follow-up time for all participants was 17.1 months.
  2. Kaplan-Meier Estimates of PFS Based on the Response Assessment by the Investigator At the Time of Final AnalysisTime frame: From date of randomization to date of data cut-off date of 21 January 2016; median follow-up for all participants was 17.7 months

Locations

288 sites in 19 countries. Site status is shown where the registry gives one.

  • University of AL Birmingham

    Birmingham, Alabama

  • Cedar Sinai Medical Center Dept of Medicine

    Los Angeles, California

  • University of California, San Francisco- California

    San Francisco, California

  • Stanford University Stanford

    Stanford, California

  • Gainesville Heme Oncology Associates

    Gainesville, Florida

  • Baptist Cancer Institute

    Jacksonville, Florida

  • Integrated Community Oncology Network

    Orange Park, Florida

  • Gulf Coast Oncology

    St. Petersburg, Florida

  • Palm Beach Cancer Institute, LLC

    West Palm Beach, Florida

  • Southern Illinois Hematology Oncology

    Centralia, Illinois

  • Orchard Healthcare Research, Inc.

    Chicago, Illinois

  • John H Stroger Hospital of Cook County

    Chicago, Illinois

  • Rush University Medical Center

    Chicago, Illinois

  • Ingalls Cancer Institute

    Harvey, Illinois

  • Cancer Center of Kansas

    Wichita, Kansas

  • Maine Center for Cancer Medicine Blood Disorders

    Scarborough, Maine

  • Center for Cancer and Blood Disorders

    Bethesda, Maryland

  • Mayo Clinic Cancer Center

    Rochester, Minnesota

  • Billings Clinic

    Billings, Montana

  • Arena Oncology Associates, PC

    Lake Success, New York

  • Dakota Cancer Institute

    Fargo, North Dakota

  • Gabrail Cancer Center Research

    Canton, Ohio

  • University Hospitals of Cleveland

    Cleveland, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Kaiser Permanente Northwest Oncology Hematology

    Portland, Oregon

  • St. Luke's Hospital and Health Network

    Allentown, Pennsylvania

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • The Cancer Center

    Collierville, Tennessee

  • University of Tennessee Cancer Institute

    Memphis, Tennessee

  • University of Texas Medical Branch

    Galveston, Texas

  • Swedish Cancer Institute

    Seattle, Washington

  • Fred Hutchinson Cancer Center

    Seattle, Washington

  • Flinders Medical Centre

    Bedford Park, Australia

  • Geelong Hospital

    Geelong, Australia

  • Gosford Hospital

    Gosford, Australia

  • Royal Brisbane and Women's Hospital

    Herston, Australia

  • Cabrini Hospital

    Malvern, Australia

  • The Royal Melbourne Hospital

    Parkville, Australia

  • Royal Perth Hospital

    Perth, Australia

  • Gold Coast Hospital

    Southport, Australia

Showing 40 of 288 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.